EIGRQ
vs
S&P 500
EIGRQ
S&P 500
Over the past 12 months, EIGRQ has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
EIGRQ vs S&P 500
Performance Gap
EIGRQ vs S&P 500
Performance By Year
EIGRQ vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Eiger BioPharmaceuticals Inc
Glance View
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. The company is headquartered in Palo Alto, California and currently employs 27 full-time employees. The company went IPO on 2014-01-30. The firm is focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV), the severe form of viral hepatitis, and other serious diseases. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing as a treatment for congenital hyperinsulinism (HI). The company is also developing lambda as an out-patient treatment for patients with mild and moderate COVID-19. The firm is also developing Avexitide as a treatment for post-bariatric hypoglycemia (PBH).
